Integrating anatomo-physiological changes and pharmacogenomics in anti-infective therapy management: is it a major concern?

Br J Clin Pharmacol. 2019 Jan;85(1):263-265. doi: 10.1111/bcp.13785. Epub 2018 Nov 16.

Abstract

Success of anti-infective therapy is a major challenge in some patients given anatomo-physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism.

Keywords: cytochrome P450 enzymes; drug metabolism; genetic polymorphism; pharmacogenomics; therapeutic drug monitoring.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Anorexia Nervosa / complications
  • Anorexia Nervosa / physiopathology*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics*
  • Azoles / administration & dosage
  • Azoles / pharmacokinetics*
  • Cytochrome P-450 CYP2C19 / genetics*
  • Cytochrome P-450 CYP2C19 / metabolism
  • Female
  • Humans
  • Intestinal Absorption / physiology
  • Pharmacogenomic Testing
  • Polymorphism, Single Nucleotide
  • Pulmonary Aspergillosis / complications
  • Pulmonary Aspergillosis / drug therapy*
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Azoles
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19